Table 2-1.
Case Study Characteristics.
| Nr | Study | #IBD pts |
IBD Type |
IBD Severity | FMT dosage | FMT delivery |
Pre-Abs / lavage | Frequency | Donor | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bennet et al. (1989).2 | 1 | UC | Severe | NR | Large volume enema's | NR | multiple ×1 | NR | 6 months |
| 2 | Borody et al. (1989).4 | 2 | UC,CD | Active | NR | NR | NR | NR | NR | 1-12months |
| 3 | Borody et al. (2001).5 | 3 | UC | Quiescent | Suspended in 200ml saline+table spoon psyllium | Enema | NR | daily × 5days | Healthy adults | 8-28 months |
| 4 | Borody et al. (2003).7 | 6 | UC | Severe | 200-300g(diluted to 200-300ml) | Enema | Vancomycin, Metronidazole and rifampicin for 7-10 days +3L oral PEG solution | daily × 5days | Family or close relation | 1-13 years |
| 5 | Borody et al. (2011).6 | 3 | IBD | IM/anti-TNF refractory-severe | NR | Enema (Self) | NR | daily&weekly X34-70 | Clinic donor, family, partner | 1-4 years |
| 6 | Borody et al. (2011).3 | 1 | UC+ITP | Chronic-relapsing UC | NR | NR | NR | NR | NR | NR |
| 7 | Kao et al. (2014).9 | 1 | IBD | Moderate-Severe | 400cc fresh fecal suspension | Colonoscopy | NR | ×3 (0,4, 10 wks) | universal donor | 2 months |
| 8 | Kellermayer et al. (2013).8 | 4 (−1a) | UC | IM/anti-TNF dependent | NR | Colonoscopy | NR | Serial | ? | >5 months |
NR=Not Reported
a
Excluded from final analysis due to enema intolerance.